Treatment with H2S donors could inhibit the transition from compensatory hypertrophy to heart failure by inducing the production of MMP‐2, inhibiting the expression of TIMP‐3 and MMP‐9, and promoting the synthesis of VEGF.155. The gene discussed is VEGFA; the disease is heart failure.